This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Maclean, D. Search for Related Content PubMed PubMed Citation Articles by Maclean, D. Social Bookmarking                         What's this?

Future/Novel Uses of Beta Blockers in Clinical Therapeutics

University of Dundee and the Tayside Health Board, Dundee, Scotland

Beta-blocker usage in the United Kingdom centers around propranolol and oxprenolol as noncardioselective drugs, atenolol and metoprolol as cardioselec tive agents, and pindolol or oxprenolol when partial agonist activity is desired. Any meaningful comparison of a novel beta blocker against the established drugs must be a variable-dose trial, for the optimum dose of any beta blocker that can be tolerated varies widely. Effective beta blockade is considered to have been achieved when the standing heart rate has been lowered to about 55 beats- /minute.

Angiology, Vol. 37, No. 3, 218-220 (1986)
DOI: 10.1177/000331978603700312


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?